Dr. Andreas Flueckiger, Andreas Flueckiger Consulting - Qepler Summits And Conferences

Dr. Andreas Flueckiger

Consultant Occupational Toxicology and Containment, Head of Occupational Health @ Roche (retired)
Andreas Flueckiger Consulting
Basel, Switzerland

Andreas Flückiger, MD, holds Swiss Governmental certifications in General Internal and Occupational Medicine.

Before his retirement from the company in 2018, he was Chief Occupational Health Officer for the Roche Group for over 32 years. In this corporate function, he managed Roche’s occupational health and it its hazard assessment programs. This activity included standard-setting, auditing and teaching activities in the broader field of SHE, but in particular in occupational health.

Between 1986 and 2018, he and his team have set health-based exposure limits for over 2000 molecules. He is has participated in numerous training courses on the GMP context in which these limits are used, in particular quality risk management in multi-product facilities.

Andreas Flückiger is a member or honorary member in several professional organizations.

He now continues to work as a consultant mainly in the areas of occupational toxicology, exposure control and general EHS matters.

Related Sessions:

2nd Annual Highly Potent APIs
Summit 2020

Assess and reduce manufacturing and handling challenges for highly potent active pharmaceutical ingredients.
  • 19 Feb 2020
  • Prague, CZ
  • Pharma
Day 1: Wednesday, 19 February 2020
CASE STUDY: PDE evaluation and OEL setting in an HPAPI environment, regulatory considerations.
  • Health Based Exposure Limits (HBELs): what are they, how are they defined, why are they needed?
  • PDEs in addition to or instead of the old standards for calculating GMP cleaning limits?
  • When are PDEs needed in GMP? Available guidance for setting such limits
  • Common pitfalls when setting HBELs
View Details

2nd Annual Highly Potent APIs
Summit 2020

Assess and reduce manufacturing and handling challenges for highly potent active pharmaceutical ingredients.
  • 19 Feb 2020
  • Prague, CZ
  • Pharma
Day 2: Thursday, 20 February 2020
CASE STUDY: Production of Highly Active Substances in Shared Facilities - A Risk for Patients?
  • Cross-contamination risk in the manufacture of HPAPIs
  • Risk mitigation measures according to ch. 5 of EMA’s GMP Guidelines
  • Examples from oral and parenteral drug manufacture
View Details